These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 32964210)

  • 1. Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply.
    Guaraldi G; Milic J; Cozzi-Lepri A; Pea F; Mussini C
    Lancet Rheumatol; 2020 Dec; 2(12):e739-e740. PubMed ID: 32964210
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
    Guaraldi G; Meschiari M; Milic J; Cozzi-Lepri A; Mussini C
    Lancet Rheumatol; 2020 Nov; 2(11):e660-e661. PubMed ID: 32838326
    [No Abstract]   [Full Text] [Related]  

  • 3. Tocilizumab in COVID-19: finding the optimal route and dose.
    Jain S; Jain S; Sharma SK
    Lancet Rheumatol; 2020 Dec; 2(12):e738-e739. PubMed ID: 32964209
    [No Abstract]   [Full Text] [Related]  

  • 4. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.
    Liu B; Qi Z
    Clin Drug Investig; 2020 Sep; 40(9):893-895. PubMed ID: 32661911
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab and liver injury in patients with COVID-19.
    Serviddio G; Villani R; Stallone G; Scioscia G; Foschino-Barbaro MP; Lacedonia D
    Therap Adv Gastroenterol; 2020; 13():1756284820959183. PubMed ID: 33101458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply.
    Gabay C; Kavanaugh A;
    Lancet; 2013 Aug; 382(9890):395. PubMed ID: 23911377
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.
    Rossi B; Nguyen LS; Zimmermann P; Boucenna F; Dubret L; Baucher L; Guillot H; Bouldouyre MA; Allenbach Y; Salem JE; Barsoum P; Oufella A; Gros H
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33080877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.
    Zeng J; Xie MH; Yang J; Chao SW; Xu EL
    World J Clin Cases; 2020 Sep; 8(17):3763-3773. PubMed ID: 32953852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab and COVID-19.
    Chaudhry D; Singh PK
    Indian J Crit Care Med; 2020 Sep; 24(9):741-743. PubMed ID: 33132549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.
    Hitawala A; Kumar S; Gopalakrishna KV
    Cureus; 2020 Jul; 12(7):e9187. PubMed ID: 32818119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: liver disease and COVID-19-not the perfect storm. Authors' reply".
    Garrido I; Liberal R; Macedo G
    Aliment Pharmacol Ther; 2020 Aug; 52(3):574-575. PubMed ID: 32656840
    [No Abstract]   [Full Text] [Related]  

  • 12. Anakinra for patients with COVID-19 - Authors' reply.
    Cavalli G; Landoni G; Zangrillo A; Dagna L
    Lancet Rheumatol; 2020 Jul; 2(7):e383-e384. PubMed ID: 32835236
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary intravascular coagulopathy in COVID-19 pneumonia - Authors' reply.
    McGonagle D; O'Donnell JS; Sharif K; Emery P; Bridgewood C
    Lancet Rheumatol; 2020 Aug; 2(8):e460-e461. PubMed ID: 32835255
    [No Abstract]   [Full Text] [Related]  

  • 14. Anakinra for severe forms of COVID-19 - Authors' reply.
    Hayem G; Huet T; Jouveshomme S; Beaussier H; Chatellier G; Mourad JJ
    Lancet Rheumatol; 2020 Oct; 2(10):e587-e588. PubMed ID: 32838321
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: population mortality from COVID-19 and latitude-data from China. Authors' reply.
    Rhodes JM; Subramanian S; Laird E; Kenny RA
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1261-1262. PubMed ID: 33016560
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: unknown denominator and misleading conclusions in Covid-19-authors' reply.
    Garrido I; Liberal R; Macedo G
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1243-1244. PubMed ID: 33016541
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: gastrointestinal symptoms pre-admission are associated with greater severity of COVID-19-authors' reply.
    Tian Y; Rong L
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1231-1232. PubMed ID: 33016539
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply.
    Taxonera C; Alba C
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1249-1250. PubMed ID: 33016549
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of anakinra in COVID-19 - Authors' reply.
    Cavalli G; Dagna L
    Lancet Rheumatol; 2020 Sep; 2(9):e524-e525. PubMed ID: 32838317
    [No Abstract]   [Full Text] [Related]  

  • 20. Mavrilimumab for severe COVID-19 - Authors' reply.
    De Luca G; Cavalli G; Campochiaro C; Della-Torre E; Dagna L
    Lancet Rheumatol; 2020 Nov; 2(11):e662-e663. PubMed ID: 33521663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.